摘要
目的:探讨西妥昔单抗联合化疗治疗大肠癌肝转移的疗效和不良反应。方法:对30例大肠癌肝转移患者应用西妥昔单抗联合奥沙利铂、5-FU、氟达拉宾(FA)化疗联合方案进行治疗,每周一次维持,完成6周用药,评价药物的近期疗效及毒副作用。结果:30例患者均完成西妥昔单抗连续6周用药,奥沙利铂、5-FU、FA化疗2周期,无CR病例,6例PR(20.00%),10例SD(33.33%),14例PD(46.67%),疾病控制率53.33%。本组30例患者经西妥昔单抗联合化疗后,发生1级皮疹15例,2级皮疹7例,低热4例,肝功能转氨酶升高4例,无结膜炎及腹泻发生。且骨髓毒性反应在联合应用西妥昔单抗下未增加,以上不良反应经对症处理后患者均可耐受。结论:西妥昔单抗联合化疗治疗肝转移性大肠癌近期疗效显著,可提高肿瘤对放化疗的敏感性。不良反应可以耐受。
Objective:To investigate cetuximab combined with chemotherapy for liver metastases of colorectal cancer efficacy and adverse reactions.Methods:30 patients with metastatic colorectal cancer patients with cetuximab plus oxaliplatin,5-FU,FA chemotherapy treatment program once a week to maintain,complete 6 weeks treatment,the evaluation of drug efficacy and side effects.Results:30 patients completed cetuximab treatment for 6 weeks,oxaliplatin,5-FU,FA 2 cycles of chemotherapy,patients without CR,6 cases of PR(20.00%),10 cases of SD(33.33%),14 cases of PD(46.67%),disease control rate of 53.33%.The group of 30 patients with cetuximab in combination with chemotherapy,the occurrence of a rash in 15 cases,2 rash in 7 cases,fever in 4 cases,4 cases of elevated liver transaminases,no conjunctivitis and diarrhea.And bone marrow toxic reaction should not,under cetuximab increased by more than symptomatic treatment in patients with adverse reactions can be tolerated.Conclusion:Cetuximab combined with chemotherapy for metastatic colorectal cancer a significant short-term effect,can increase the sensitivity of tumor to chemotherapy.Adverse reactions can be tolerated.
出处
《中外医学研究》
2012年第12期7-8,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
结直肠癌
西妥昔单抗
化疗
Colorectal Cancer
Cetuximab
Chemotherapy